Overview

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2030-10-30

Target enrollment:

Participant gender:

Summary

Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA), had better tumor control than those having ADT and NHA.

Phase:

PHASE2

Details

Lead Sponsor:

Yung NA

Collaborators:

Huashan Hospital
Ruijin Hospital

Treatments:

Androgen Antagonists
dapagliflozin